Large Cap Biopharmaceutical Companies – Q1 2020 Update
The IBB is at $122.69 near the 52 week high but short of 5 year high of $132.53 from Jy ’15.
- FWD PEs of sector are still lower than the market with S&P-500 at 18.9x. Good growth expected.
- Our Top Picks have done well especially after October 2019 re-balancing: ABBV BMY MRK RHHBY (not in data-ADR). We favored large caps over smaller caps recently.
- Best stock performance for 12 mo. period are BMY -(CELG) and VRTX.
- GILD remains a laggard and must do a deal in 2020.
- BIIB should have clinical data on Alzheimer’s disease program by H2 2020.
- Alexion (ALXN) is the worse 12 mo. performer.
- The Healthcare Select SPDR (XLV) beat the IBB.
| COMPANY | Ticker | Price | 2017 | Price | Price | MCap | % Perform | |||||
| 1/15/18 | Rev$B | 2/10/20 | 11/1/19 | 2020 | 12 mos | FWD | Analyst | % | ||||
| 2018 | $ | $B | % Perform | P/S | PE | Recom | Div | |||||
| Abbvie | ABBV | 100.340 | 27.27 | 94.75 | 81.75 | 140 | 18.78 | 4.27 | 9.36 | 2.2 | 4.99 | |
| Alexion | ALXN | 122.710 | 3.47 | 101.01 | 109.38 | 22.36 | -15.86 | 4.64 | 8.29 | 1.9 | ||
| Amgen | AMGN | 185.040 | 23 | 227.42 | 217.95 | 134 | 22.41 | 5.84 | 13.27 | 2.3 | 2.81 | |
| Biogen | BIIB | 335.950 | 11.84 | 338.93 | 299.2 | 60.89 | 6.96 | 4.28 | 10.48 | 2.7 | ||
| Bristol Myers | BMY | 62.810 | 19.92 | 66.91 | 57.16 | 156.85 | 33.55 | 6.08 | 8.93 | 1.9 | 2.69 | |
| Celgene* (BMY) | CELG | 106.000 | 12.5 | 108.24 | 108.53 | 77 | n/a | 4.69 | 8.7 | 2.9 | ||
| Gilead Sci | GILD | 79.020 | 27.48 | 68.99 | 64.66 | 87.28 | 2.03 | 3.89 | 10.86 | 2.4 | 3.94 | |
| Merck | MRK | 58.660 | 39.8 | 85.66 | 84.94 | 218.1 | 11.67 | 4.69 | 13.65 | 1.9 | 2.85 | |
| Regeneron | REGN | 366.960 | 5.52 | 386.21 | 310.48 | 42.4 | -5.46 | 5.41 | 13.72 | 2.4 | ||
| Vertex | VRTX | 158.000 | 2.3 | 244.75 | 200.94 | 50.25 | 34.83 | 15.06 | 24.12 | 1.9 | ||
| XBI | 96.88 | 83.66 | 14.73 | |||||||||
| IBB | 122.73 | 109.85 | 12.17 | |||||||||
| FBT | 151.72 | 132.92 | 7.06 | |||||||||
| FBIOX | 22.52 | 20.26 | 13.34 | |||||||||
| XLV | 103.59 | 94.87 | 15.32 | |||||||||
| XPH | 47.29 | 39.47 | 16.94 | |||||||||
| QQQ | 231.97 | 36.1 |
=============
2019 LARGE CAP Biopharmaceutical Metrics and Valuations
Compared to 2018
| COMPANY | Ticker | Price | 2017 | Price | Price | MCap |
% Perform
|
|||||
| 1/15/18 | Rev$B | 12/18 | 11/1/19 | 2019 | 2019 | FWD | Analyst | % | ||||
| $B | YTD | P/S | PE | Recom | Div | |||||||
| Abbvie | ABBV | 100.340 | 27.27 | 92.19 | 81.75 | 121 | -10.85 | 3.71 | 8.55 | 2.1 | 5.24 | |
| Alexion | ALXN | 122.710 | 3.47 | 97.36 | 109.38 | 24.42 | 7.5 | 5.16 | 9.77 | 1.8 | ||
| Amgen | AMGN | 185.040 | 23 | 194.67 | 217.95 | 130.55 | 11.13 | 5.58 | 13.8 | 2.3 | 2.66 | |
| Biogen | BIIB | 335.950 | 11.84 | 300.92 | 299.2 | 53.9 | -1.58 | 3.79 | 9.09 | 2.7 | ||
| Bristol Myers | BMY | 62.810 | 19.92 | 51.98 | 57.16 | 93.84 | 9.42 | 3.93 | 9.03 | 2 | 2.87 | |
| Celgene | CELG | 106.000 | 12.5 | 64.09 | 108.53 | 76.7 | 62.11 | 4.69 | 8.7 | 2.9 | ||
| Gilead Sci | GILD | 79.020 | 27.48 | 62.55 | 64.66 | 82.12 | 0.43 | 3.68 | 9.3 | 2.1 | 3.9 | |
| Merck | MRK | 58.660 | 39.8 | 76.41 | 84.94 | 221.88 | 14.64 | 4.83 | 15.26 | 1.8 | 2.59 | |
| Regeneron | REGN | 366.960 | 5.52 | 373.5 | 310.48 | 33.07 | -17.76 | 4.57 | 12.37 | 2.5 | ||
| Vertex | VRTX | 158.000 | 2.3 | 165.71 | 200.94 | 50.25 | 19.14 | 13.88 | 30.48 | 2 | ||
| XBI | 71.75 | 83.66 | 16.6 | |||||||||
| IBB | 96.43 | 109.85 | 13.92 | |||||||||
| FBT | 124.2 | 132.92 | 7.02 | |||||||||
| FBIOX | 17.74 | 20.26 | 14.21 | |||||||||
| XLV | 86.46 | 94.87 | 9.66 | |||||||||
| XPH | 39.47 | 7.78 | ||||||||||